BEBT-808

LE PONT-DE-CLAIX, France, Sept. 18, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe and the latest capacity expansion of the BD Neopak™ Glass Prefillable Syringe platform to serve the growing market for biologic therapies. Continue Reading BD announces the commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe and the latest capacity expansion of the BD Neopak™ Glass Prefillable Syringe platform to serve the growing market for biologic therapies. The BD Neopak™ Glass Prefillable Syringe platform is designed to address key development needs for biologic drugs and our customers have received approval to utilize this platform for more than 24 indications, including Crohn's disease, atopic dermatitis, cardiovascular disease and various rare diseases. BD has expanded usability of this platform with the commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe. This solution features an 8-millimeter needle length and thinner wall cannula to optimize subcutaneous delivery of higher viscosity drug profiles by reducing the injection force and time required for a fixed solution viscosity1,2*. This improvement allows pharmaceutical developers to break design barriers, enhancing flow and usability beyond today's limits versus a standard half-inch needle3*. "BD is seeing significant growth in the biologics segment, driven by novel drug formulations across indications such as metabolic disorders and oncology," said Patrick Jeukenne, president of BD Pharmaceutical Systems. "With over 30 drugs approved across 12 markets and many more in development with the BD Neopak™ Glass Prefillable Syringe platform, flexibility is crucial. As a global leader in prefillable drug-delivery systems, BD aims to evolve as rapidly as the global biologics pipeline to enable supply and delivery of these drugs for patients worldwide." In addition to the usability enhancements, our manufacturing site in Le Pont-de-Claix, France has successfully integrated a high-volume manufacturing line for the BD Neopak™ Glass Prefillable Syringe platform, increasing the production capacity of a single line by sevenfold4. This achievement marks a significant milestone for BD, enabling unprecedented large-scale production of advanced BD glass syringes. The launch of our BD Neopak™ XtraFlow™ Glass Prefillable Syringe allows developers to take advantage of a single platform approach while dismantling existing design barriers such as drug viscosity. The successful addition of the high-volume line at the Pont-de-Claix site allows BD to be more resilient to supply constraints and further demonstrates our commitment to continuously evolve to meet the needs of our pharmaceutical partners and patients worldwide. These expansions add to BD's leadership in offering a broad range of injection solutions to enable delivery of treatments such as GLP-1s, antibodies, and other next generation treatments for chronic disease. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at , X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Forward-Looking Statements This press release contains certain forward-looking statements regarding the BD Neopak™ Glass Prefillable Syringe platform. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including, without limitation, challenges inherent in product development, competitive factors, including the development of new technologies or products by other companies, changes in healthcare and drug delivery, the impact of governmental regulation, future market conditions, manufacturing difficulties or delays, or other factors listed in BD's 2023 Annual Report on Form 10-K and other filings with the SEC. BD expressly disclaims any undertaking to update any forward-looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable laws or regulations. 1. Injection time and ejection force calculation [internal study], Le Pont-de-Claix, France; Becton, Dickinson and Company, 2021 2. BD NeopakTM XtraFlowTM 2.25 mL prototype evaluation [internal study] , Le Pont-de-Claix, France; Becton, Dickinson and Company, 2020 3. Pager et al. (2020), "User experience for manual injection of 2 mL viscous solutions is enhanced by a new prefillable syringe with staked 8 mm ultra-thin wall needle", Expert Opinion on Drug Delivery, . 4. BD data on file *When compared to 12.7 mm special thin wall needle SOURCE BD (Becton, Dickinson and Company) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Noom will pair its new product, Noom GLP-1Rx, with its nutrition and exercise program designed to help users prevent muscle loss. The company also offers a "taper-off guarantee." Noom is the latest digital health company to jump into the off-label weight loss drug market to make medications more accessible to consumers.The company, which developed an app that helps people lose weight by focusing on behavioral change, launched a new service to offer a compounded GLP-1 drug at a starting price of $149 for the first month and then $279 for subsequent months. Noom contends that market prices of brand-name medications can be 8x higher. Noom will pair the new product, Noom GLP-1Rx, with its nutrition and exercise program designed to help users prevent muscle loss. The company also offers a "taper-off guarantee" by providing a protocol for users to gradually reduce reliance on the medications while maintaining their weight loss, the company said in a press release.The program provides a year of free Noom or substantial medication discounts to anyone who regains the weight within 18 months following a 12-month course of Noom GLP-1Rx, including Noom’s taper protocol.The company already offers access to branded GLP-1 medications such a Ozempic, Zepbound, Wegovy and Mounjaro. The off-label medications contain the same active ingredient, compounded semaglutide, as major brand-name medications. These medications are provided in partnership with a Food and Drug Administration-regulated 503B compounding pharmacy, the company said.Through this new offering, Noom members will be evaluated by board-certified physicians with expertise in obesity and weight loss to qualify for the weight loss medication. Medications will be delivered to a patient’s door in seven days from the time of order, according to the company. The price tag on branded weight loss drugs like Wegovy can total more than $1,000 a month per person without insurance.“Noom GLP-1Rx addresses the biggest real-world problems with GLP-1s: poor persistence and lean muscle mass loss,” Noom CEO Geoff Cook said in a statement. “Evidence demonstrates the vast majority of people, 6 out of 7, are not on these medications forever. They lose lean muscle mass and regain the weight, risking conditions like sarcopenic obesity, leaving them potentially worse off than before they started the medication. People need affordable access to these important medications, and then they need an offramp off of them. We designed Noom to be that offramp. Our goal is not to sell more medications; it’s to achieve sustainable, lasting weight loss for our members.”Noom is the latest digital health company to offer cheaper alternatives to expensive, trendy weight loss drugs. Virtual marketplace Sesame rolled out a new weight loss program that gives eligible consumers access to compounded semaglutide, an ingredient in blockbuster obesity drugs Wegovy and Ozempic, for $249 a month.Hims & Hers and Ro also offer direct-to-consumer weight loss programs and, for eligible consumers, access to compounded semaglutide drugs. Ro also provides access to branded weight loss drugs like Wegovy and Ozempic.Hims & Hers launched its weight loss program in December and recently added compounded GLP-1 medications to its offerings. Through Hims & Hers, weight loss medications start at $79 per month for oral medication kits and $199 per month for compounded GLP-1 injections, according to the company. Pricing includes unlimited medical consultations with a licensed provider, the company said.Federal lawmakers, particularly Sen. Bernie Sanders, I-Vermont, chairman of the Senate Health, Education, Labor, and Pensions Committee, have questioned the steep prices of drugs like Ozempic and Wegovy. In a letter to the CEO of Novo Nordisk, Sanders contends that Novo charges Americans with obesity $1,349 a month for Wegovy, while this same exact product can be purchased for just $140 in Germany and $92 in the U.K.Novo Nordisk CEO Lars Fruergaard Jørgensen is scheduled to testify before the Senate HELP Committee on Sept. 24. More than 250 clinicians signed a letter (PDF) to the Senate HELP Committee expressing concern about the lack of patient access to novel non-insulin diabetes and weight loss medications due to exorbitant prices set by manufacturers. There can also be limited availability of branded weight loss medications due to drug shortages.Noom also is calling on policymakers and regulators to "take into account this increase in demand and maintain compounding exemptions until the price of the brand-name medications in New York and Los Angeles match their price in London and Sydney," Cook said in a statement. "The bottom line is these medications should be $200-$300 a month, not $1,300. Policymakers and regulators should demand this or keep the shortage in place to meet the very real demand at these lower prices—the same prices at which these medications are available in the rest of the world. As a longer term solution to address this problem, we also call for bi-partisan legislation to cap drug prices or extend shortages until the brand-name price falls. More supply at a reasonable price is needed right now, not less," Cook said.